The co-selection of AKT1 and EGFR as core targets suggests that IPTF may contribute to suppressing NSCLC progression by synergistically regulating the PI3K/AKT and EGFR-MAPK signaling ways. This evidence concerns the gene AKT1 and non-small cell lung carcinoma.